8-K: Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025, Improves Profit Outlook

Teva Pharmaceutical Industries Ltd. reports a strong Q1 2025 with revenue growth and an improved profit outlook, driven by key innovative medicines.

Summary

• Teva Pharmaceutical Industries Ltd. announced its Q1 2025 financial results, marking the ninth consecutive quarter of revenue growth.
• Q1 2025 revenues reached $3.9 billion, a 5% increase in local currency terms.
• Key innovative medicines like AUSTEDO, AJOVY, and UZEDY showed strong growth, collectively increasing by approximately 40%.
• The company is on track to achieve a 30% operating profit margin by 2027, aligning with its Pivot to Growth Strategy.
• Teva is targeting approximately $700 million in net savings by 2027 through targeted programs.
• The full-year 2025 business outlook has been revised, with revenue expected to be between $16.8 and $17.2 billion.
• Non-GAAP operating income is projected to be between $4.3 and $4.6 billion, and Non-GAAP diluted EPS is expected to be between $2.45 and $2.65.
• Free cash flow is anticipated to be between $1.6 and $1.9 billion.
• Teva's generics business grew across all regions, with increases of 5% in the U.S., 1% in Europe, and 2% in International Markets, all in local currency terms.
• The company expects to initiate the Phase 3 program for duvakitug (Anti-TL1A) in H2 2025 and is preparing for an olanzapine LAI FDA NDA submission in H2 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong growth in key products and an improved financial forecast. While there are some challenges, the overall tone is optimistic and confident.

Positives

• Teva achieved its ninth consecutive quarter of revenue growth.
• Key innovative products like AUSTEDO, AJOVY, and UZEDY are driving growth.
• The company is making progress towards its 2027 operating margin target of 30%.
• The generics business is performing well across all regions.
• Teva is actively managing its portfolio and optimizing its global manufacturing footprint.
• The company is focused on debt repayment, having repaid $1.4 billion at maturity.
• The 2025 outlook has been revised upwards for operating income and EPS.
• The FDA approved SELARSDI (ustekinumab-aekn) injection as interchangeable with the reference biologic Stelara (ustekinumab).

Negatives

• Exchange rate movements negatively impacted revenues by $101 million and operating income by $50 million.
• Revenues in the Europe segment decreased by 6%, or 2% in local currency terms.
• COPAXONE revenues in Europe decreased by 27% due to price reductions and volume decline.
• International Markets segment revenues decreased by 2% due to exchange rate fluctuations.
• Gross profit margin in the Europe segment decreased to 55.1% due to hedging activities and unfavorable product mix.
• Profit from the Europe segment decreased by 22% due to lower gross profit.
• Profit from the International Markets segment decreased by 17% due to lower gross profit.

Risks

• The price-setting process for AUSTEDO and AUSTEDO XR by the Centers for Medicare and Medicaid Services (CMS) could impact future revenues.
• Teva faces competition for its innovative medicines and generic products.
• The company's significant indebtedness could limit its ability to make new investments.
• Global economic conditions and political instability could impact Teva's business.
• Failure to comply with complex legal and regulatory environments could lead to negative consequences.
• The ongoing conflict between Russia and Ukraine and the state of war declared in Israel could disrupt operations.
• Exposure to currency fluctuations and restrictions could impact financial results.
• Potential impairments of long-lived assets could negatively affect the balance sheet.
• Changes in international trade policies, including tariffs, could impact sales and raw material costs.

Future Outlook

Teva has revised its full-year 2025 outlook, expecting revenues of $16.8 $17.2 billion, Non-GAAP operating income of $4.3 $4.6 billion, Adjusted EBITDA of $4.7 $5.0 billion, and Non-GAAP diluted EPS of $2.45 $2.65. The company also reaffirmed its 2027 targets, including a 30% operating margin.

Management Comments

• Mr. Richard Francis, Teva's President and CEO, said, Teva had a solid start to the year, with its ninth consecutive quarter of revenue growth, delivering global revenues of $3.9 billion, an increase of 5% in local currency terms compared to the first quarter of 2024.
• Mr. Francis continued, Now entering the Acceleration Phase of our Pivot to Growth Strategy, we have a clear roadmap to continue Teva's transformation into a leading biopharmaceutical company with an expected 30% operating margin and today have announced ~$700 million net savings by 2027.

Industry Context

Teva's focus on innovative medicines and biosimilars aligns with the broader industry trend of companies seeking growth in higher-margin products. The company's efforts to streamline operations and reduce debt are also consistent with industry-wide efficiency initiatives. The approval of SELARSDI as interchangeable with Stelara is a significant development in the biosimilar market, potentially increasing access to more affordable treatment options.

Comparison to Industry Standards

• Teva's revenue growth of 5% in local currency terms is comparable to other major pharmaceutical companies, such as Novartis, which reported a similar growth rate in its Q1 2025 results.
• The company's target of achieving a 30% operating margin by 2027 is ambitious but achievable, considering the industry average for operating margins is around 25-35% for large pharmaceutical firms like Johnson & Johnson and Pfizer.
• Teva's focus on biosimilars is in line with companies like Amgen and Biogen, which are also investing heavily in this area to capitalize on the growing demand for affordable biologics.
• The successful launch of SELARSDI as an interchangeable biosimilar positions Teva competitively against companies like Viatris and Sandoz, which are also key players in the biosimilar market.

Stakeholder Impact

• Shareholders will benefit from the improved financial outlook and growth in key products.
• Employees may experience changes as the company continues its organizational transformation and cost-saving initiatives.
• Customers will have access to a broader range of medicines, including innovative products and biosimilars.
• Suppliers may be affected by the company's efforts to optimize its global manufacturing footprint.
• Creditors will see improved financial stability as the company focuses on debt repayment.

Next Steps

• Initiate Phase 3 program for duvakitug (Anti-TL1A) in H2 2025.
• Prepare for olanzapine LAI FDA NDA submission in H2 2025.
• Continue efforts to sell the active-pharmaceutical ingredient (API) business.
• Host Innovation & Strategy Day on May 29, 2025.
• Pursue additional submissions for AUSTEDO in various markets.
• Launch UZEDY in other countries around the world.

Key Dates

Keywords

Teva, Pharmaceutical, Financial Results, Q1 2025, Revenue Growth, AUSTEDO, AJOVY, UZEDY, Generics, Operating Margin, Outlook, Biosimilars